EP3883579
Samsett meðferð sem nær yfir KRAS-G12C hindra og einn eða fleiri viðbótar lyfjafræðilega virka miðla til meðhöndlunar á krabbameinum
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
18.11.2019EP published:
24.12.2025EP application number:
19886683.2
EP translation filed:
18.2.2026Grant published:
11.3.2026EPO information:
European Patent Register
Max expiry date:
17.11.2039Expiry date:
17.11.2026
Title in English:
COMBINATION THERAPY INCLUDING A KRAS-G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERSLanguage of the patent:
English
Timeline
Today
18.11.2019EP application
24.12.2025EP Publication
18.2.2026Translation submitted
11.3.2026Registration published
17.11.2026Expires
Owner
Name:
Amgen Inc.Address:
One Amgen Center Drive, Thousand Oaks CA 91320, US
Inventor
Name:
LIPFORD, James RussellAddress:
Thousand Oaks, CA 91320-1799, US
Name:
CANON, Jude RobertAddress:
Thousand Oaks, CA 91320-1799, US
Name:
SAIKI, Anne Y.Address:
Thousand Oaks, CA 91320-1799, US
Name:
REX, Karen LouiseAddress:
Thousand Oaks, CA 91320-1799, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201862769355 PDate:
19.11.2018Country:
US
Number:
201962821376 PDate:
20.3.2019Country:
US
Number:
201962865819 PDate:
24.6.2019Country:
US
Classification
Categories:
A61K 31/555, A61K 31/506, A61K 31/519, A61K 45/06, A61P 35/00, A61K 39/395, C07K 16/28